



UNIVERSITY OF LEEDS

This is a repository copy of *Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer*.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/109312/>

Version: Supplemental Material

---

**Article:**

Bell, R, Brown, JM [orcid.org/0000-0002-2719-7064](http://orcid.org/0000-0002-2719-7064), Parmar, M et al. (18 more authors) (2017) Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. *Annals of Oncology*, 28 (4). pp. 754-760. ISSN 0923-7534

<https://doi.org/10.1093/annonc/mdw665>

---

© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. This is a pre-copyedited, author-produced PDF of an article accepted for publication in *Annals of Oncology* following peer review. The version of record, 'Bell, R, Brown, JM, Parmar, M et al (2017) Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. *Annals of Oncology*, 28 (4). pp. 754-760,' doi: 10.1093/annonc/mdw665; is available online at: <https://doi.org/10.1093/annonc/mdw665>.

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

## Enrolment

Assessed for eligibility ( $N = 3558$ )

Excluded ( $N = 967$ )\*

Randomized ( $N = 2591$ )

## Randomization

Randomized to chemotherapy alone ( $N = 1290$ )

- Received allocated treatment ( $N = 1270$ )
- Did not receive allocated treatment
  - No study drug received ( $N = 18$ )
  - Received bevacizumab ( $N = 2$ )

Randomized to chemotherapy plus bevacizumab ( $N = 1301$ )

- Received allocated treatment ( $N = 1286$ )
- Did not receive allocated treatment
  - No study drug received ( $N = 14$ )
  - Received no bevacizumab ( $N = 1$ )

## Analysis

Analyzed for efficacy ( $N = 1290$ )  
Analyzed for safety ( $N = 1271$ )

Analyzed for efficacy ( $N = 1301$ )  
Analyzed for safety ( $N = 1288$ )

## Follow-up

- Alive in follow-up/survival follow-up ( $N = 1001$ )
- Lost to follow-up ( $N = 140$ )
- Death ( $N = 149$ )

- Alive in follow-up/survival follow-up ( $N = 1047$ )
- Lost to follow-up ( $N = 110$ )
- Death ( $N = 144$ )